Oncology | Tracking rapid innovation in cancer care

News

AstraZeneca raises guidance on stellar cancer drugs growth

AZ reports strong financial results for 2025, and provides a first peek at the data for its oral GLP-1 contender elecoglipron.

News

Takeda signs $1.7bn AI alliance with Iambic

Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders.

News

Flagship's AI-focused Generate Biomedicines files IPO

Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly asthma drug.

News

Grail multi-cancer test taps into Hims & Hers network

Grail has teamed up with telehealth company Hims & Hers to boost access to its recently filed Galleri blood test for cancer screening.

News

Eikon, Veradermics close IPOs, as Salspera joins queue

Eikon and Veradermics push upsized IPOs over the line, as Salspera, which is developing live microbial immunotherapies for cancer, seeks a listing.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J bulks up in bispecifics with $1.3bn Xencor alliance

Fresh from claiming its first bispecific antibody approval, Johnson & Johnson has delved deeper into the category with a deal to license a drug for B-cell cancers developed by Xencor.

News

Enhertu nabs speedy FDA review for earlier use in breast can...

Hard on the heels of impressive new data for Enhertu as a second-line therapy for breast cancer, AstraZeneca and Daiichi Sankyo have claimed FDA breakthrough status for the drug that should

News

Kite claims a first for CAR-T Tecartus in adult leukaemia

The FDA has approved Kite Pharma's Tecartus as a treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), making CAR-T therapy an option for an

News

AstraZeneca raises guidance on stellar cancer drugs growth

AZ reports strong financial results for 2025, and provides a first peek at the data for its oral GLP-1 contender elecoglipron.

News

Takeda signs $1.7bn AI alliance with Iambic

Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders.

Views & Analysis

Oncology

A cancer treatment modality that prioritises QoL, with Ben Z...

Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.

Oncology

Improving breast cancer outcomes in sub-Saharan Africa

New funding from The Pfizer Foundation will support breast cancer efforts in Kenya by the Academic Model Providing Access to Healthcare (AMPATH).

Deep Dive

Oncology

City Cancer Challenge: A gender-focused revolution in global...

Oncology

Cell and gene therapies: Stagnation or maturation?

Webinars

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Oncology

Sponsored

How can digital and AI optimise the delivery of patient supp...

How can digital and AI optimise the delivery of patient support programs in cancer?

Oncology

Sponsored

Clinical decision-making insights for haem/oncs

Despite the effects of countries’ lockdown policies, a plethora of clinical trial readouts continue to emerge providing several decision-making challenges for healthcare professionals.

Oncology

IQVIA_webinar_holding_slide-07.04.20-1200x675-NEW

Sponsored

Unlocking health data to improve oncology outcomes

The NHS’ globally unique health data ecosystem has the potential to improve health outcomes.

Podcasts

Oncology

pharmaphorum podcast Episode 241, Mohit Manrao, AstraZeneca

On AI and equity in the cancer setting, with Mohit Manrao

Deep Dive editor Eloise McLennan speaks with Mohit Manrao, SVP, head of US oncology at AstraZeneca, and president of the AstraZeneca Foundation.

Oncology

pharmaphorum podcast Episode 238, Andrew Newland, ANGLE

Aligning with national efforts to modernise cancer diagnosti...

Andrew Newland, former CEO of ANGLE, explains why live cell liquid biopsies should become standard in oncology.

Oncology

pharmaphorum podcast Episode 229, Craig Eagle, Guardant Health

How blood tests can inform cancer treatment decisions, with ...

Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.

Video

Oncology

A cancer treatment modality that prioritises QoL, with Ben Z...

Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.

Oncology

Engineering “smarter” cells, with Tim Lu

Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone

Oncology

Astellas’ banner year and focused R&D strategy, with Adam Pe...

At JPM2026, Astellas' chief strategy officer Adam Pearson walked pharmaphorum through the company’s four-pillared R&D strategy.

White Papers

Oncology

Life Sciences Industry Report - Part 5 feature image

Life Sciences Industry Report - Oncology

Developments in the oncology space in 2024 brought hope to both industry and patients.

Oncology

Sponsored

Patient Centricity to Integration: Enhancing Cancer Outcomes

We are living in an era of unprecedented advances in cancer treatments with transformative therapies being regularly approved.

White Papers

Sponsored

How pharma can help the post-COVID recovery of European canc...

The new Cancer Care in Europe: Recovering from COVID-19 Disruption white paper assesses the disruption to patient care and the changes physicians i

Event

Oncology

Partner Content

Tumor Models Summit

The Tumour Models Summit London returns to unite 130+ tumour modelling experts from pharma, biotech, and model providers from across the UK and Europe

Spotlight on

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content coming to you from onsite in Chicago. We’ll have features and video content rolling out as the presentations unfold day by day.

Spotlight on

ESMO 2025

Spotlight On: ESMO 2025 collates pharmaphorum's coverage of the Congress, including expert insights and interviews.

Oncology

Sponsored

How can digital and AI optimise the delivery of patient supp...

How can digital and AI optimise the delivery of patient support programs in cancer?

Oncology

Sponsored

Meeting MSL training needs in an evolving landscape

As medical treatments become more complex, the role of the Medical Science Liaison (MSL) has never been more important.

Oncology

ZS_webinar_holding_slide-approved_13.09.19

Sponsored

Cost & Management of Oncology Combination Regimens

Overview

Partner Content

Citius Oncology Signs Exclusive Commercialization Agreement ...

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

Oncology

Partner Content

Tumor Models Summit

The Tumour Models Summit London returns to unite 130+ tumour modelling experts from pharma, biotech, and model providers from across the UK and Europe

Oncology

Partner Content

3rd Cell Therapy for Autoimmune Disease Summit

Over the past year autoimmune cell therapies has seen billion-dollar investments, consistent innovation, and success stories

AstraZeneca raises guidance on stellar cancer drugs growth

Takeda signs $1.7bn AI alliance with Iambic

Flagship's AI-focused Generate Biomedicines files IPO

Grail multi-cancer test taps into Hims & Hers network

Eikon, Veradermics close IPOs, as Salspera joins queue

J&J bulks up in bispecifics with $1.3bn Xencor alliance

Enhertu nabs speedy FDA review for earlier use in breast can...

Kite claims a first for CAR-T Tecartus in adult leukaemia

AstraZeneca raises guidance on stellar cancer drugs growth

Takeda signs $1.7bn AI alliance with Iambic

A cancer treatment modality that prioritises QoL, with Ben Z...

Improving breast cancer outcomes in sub-Saharan Africa

City Cancer Challenge: A gender-focused revolution in global...

Cell and gene therapies: Stagnation or maturation?

How can digital and AI optimise the delivery of patient supp...

Clinical decision-making insights for haem/oncs

Unlocking health data to improve oncology outcomes

On AI and equity in the cancer setting, with Mohit Manrao

Aligning with national efforts to modernise cancer diagnosti...

How blood tests can inform cancer treatment decisions, with ...

A cancer treatment modality that prioritises QoL, with Ben Z...

Engineering “smarter” cells, with Tim Lu

Astellas’ banner year and focused R&D strategy, with Adam Pe...

Life Sciences Industry Report - Oncology

Patient Centricity to Integration: Enhancing Cancer Outcomes

How pharma can help the post-COVID recovery of European canc...

Tumor Models Summit

ASCO 2025

ESMO 2025

How can digital and AI optimise the delivery of patient supp...

Meeting MSL training needs in an evolving landscape

Cost & Management of Oncology Combination Regimens

Citius Oncology Signs Exclusive Commercialization Agreement ...

Tumor Models Summit

3rd Cell Therapy for Autoimmune Disease Summit

Novo Nordisk's Wegovy pill ad 'misleading', says FDA

How to meet your physicians where they are online

News

Views & Analysis

Deep Dive

Editor's Picks

Webinars

Podcasts

Video

White Papers

Event

Debates & Insight

Partner Content

Editor's Picks